Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway

Toxicology and Applied Pharmacology

Volumn 259, Issue 3, 2012, Pages 402-410

  Tsubaki, Masanobu ^a   Satou, Takao ^b   Itoh, Tatsuki ^b   Imano, Motohiro ^b   Ogaki, Mitsuhiko ^c   Yanae, Masashi ^a,b   Nishida, Shozo ^a  

^a KINKI UNIVERSITY   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Department of Pharmacy   (Japan)

Author keywords

Akt; Bisphosphonate; ERK; Osteosarcoma; Ras

Indexed keywords

BETA ACTIN; COLLAGEN TYPE 1; FIBRONECTIN; GELATINASE A; GELATINASE B; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERSTITIAL COLLAGENASE; LAMININ; MESSENGER RNA; MINODRONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAS PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PRENYLATION; SIGNAL TRANSDUCTION; VISCERAL METASTASIS;

ANIMALS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; DIPHOSPHONATES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; IMIDAZOLES; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C3H; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OSTEOSARCOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; RNA, MESSENGER;

EID: 84858080102     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.01.024     Document Type: Article

References (37)

1. Bianchini F., D'Alessio S., Fibbi G., Del R.M., Calorini L. Cytokine-dependent invasiveness in B16 murine melanoma cells: role of uPA system and MMP-9. Oncol. Rep. 2006, 15:709-714.
2. Bjørnland K., Flatmark K., Pettersen S., Aaasen A.O., Fodstad O., Maelandsmo G.M. Matrix metalloproteinases participate in osteosarcoma invasion. J. Surg. Res. 2005, 127:151-156.
3. Blum R., Cox A.D., Kloog Y. Inhibitors of chronically active Ras: potential for treatment of human malignancies. Recent Pat. Anticancer Drug Discov. 2008, 3:31-47.
4. Boissier S., Ferreras M., Peyruchaud O., Magnetto S., Ebetino F.H., Colombel M., et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastasis. Cancer Res. 2000, 60:2949-2954.
5. Chakraborti S., Mandal M., Das S., Mandal A., Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol. Cell. Biochem. 2003, 253:269-285.
6. Clézardin P., Gligorov J., Delmas P. Mechanisms of action of bisphosphonates on tumor cells and prospects for use in the treatment of malignant osteolysis. Joint Bone Spine 2000, 67:22-29.
7. Cole G.W., Alleva A.M., Zuo J.T., Sehgal S.S., Yeow W.S., Schrump D.S., et al. Nguyen DM. Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126. Anticancer. Res. 2006, 26:809-821.
8. Eble J.A., Haier J. Integrins in cancer treatment. Curr. Cancer Drug Targets 2006, 6:89-105.
9. Ellerbroek S.M., Fishman D.A., Kearns A.S., Bafetti L.M., Stack M.S. Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through beta1 integrin. Cancer Res. 1999, 59:1635-1641.
10. Futamura M., Kamiya S., Tsukamoto M., Hirano A., Monden Y., Arakawa H., et al. Malolactomycin D, a potent inhibitor of transcription controlled by the Ras responsive element, inhibits Ras-mediated transformation activity with suppression of MMP-1 and MMP-9 in NIH3T3 cells. Oncogene 2001, 20:6724-6730.
11. Henson E.S., Gibson S.B. Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. Cell. Signal. 2006, 18:2089-2097.
12. Himelstein B.P., Asada N., Carlton M.R., Collins M.H. Matrix metalloproteinase-9 (MMP-9) expression in childhood osseous osteosarcoma. Med. Pediatr. Oncol. 1998, 31:471-474.
13. Kawata R., Shimada T., Maruyama S., Hisa Y., Takenaka H., Murakami Y. Enhanced production of matrix metalloproteinase-2 in human head and neck carcinomas is correlated with lymph node metastasis. Acta Otolaryngol. 2002, 122:101-106.
14. Kim E.Y., Seo J.M., Cho K.J., Kim J.H. Ras-induced invasion and metastasis are regulated by a leukotriene B4 receptor BLT2-linked pathway. Oncogene 2010, 29:1167-1178.
15. Lauer J.L., Furcht L.T., Fields G.B. Inhibition of melanoma cell binding to type IV collagen by analogs of cell adhesion regulator. J. Med. Chem. 1997, 40:3077-3084.
16. Li C., Wang W., Wang H., Zhong Y., Di J., Lin Y. Proteomic analysis of proteins differentially expressed in uterine lymphocytes obtained from wild-type and NOD mice. J. Cell. Biochem. 2009, 108:447-457.
17. Liau S.S., Jazag A., Whang E.E. HMGA1 is a determinant of cellular invasiveness and in vivo metastatic potential in pancreatic adenocarcinoma. Cancer Res. 2006, 66:11613-11622.
18. Link M.P., Goorin A.M., Horowitz M., Meyer W.H., Belasco J., Baker A., Ayala A., Shuster J. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin. Orthop. Relat. Res. 1991, 270:8-14.
19. Liotta L.A., Tryggvason K., Garbisa S., Hart I., Foltz C.M., Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980, 284:67-68.
20. Mathias R.A., Chen Y.S., Wang B., Ji H., Kapp E.A., Moritz R.L., et al. Extracellular remodelling during oncogenic Ras-induced epithelial-mesenchymal transition facilitates MDCK cell migration. J. Proteome Res. 2010, 9:1007-1019.
21. Matsuoka H., Tsubaki M., Yamazoe Y., Ogaki M., Satou T., Itoh T., et al. Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways. Exp. Cell Res. 2009, 315:2022-2032.
22. Montague R., Hart C.A., George N.J., Ramani V.A., Brown M.D., Clarke N.W. Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer. Eur. Urol. 2004, 46:389-402.
23. Nam J.S., Ino Y., Sakamoto M., Hirohashi S. Ras farnesylation inhibitor FTI-277 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Jpn. J. Cancer Res. 2002, 93:1020-1028.
24. Nishida S., Fujii Y., Yoshioka S., Kikuichi S., Tsubaki M., Irimajiri K. A new bisphosphonate, YM529 induces apoptosis in HL60 cells by decreasing phosphorylation of single survival signal ERK. Life Sci. 2003, 73:2655-2664.
25. Nishida S., Kikuichi S., Haga H., Yoshioka S., Tsubaki M., Fujii K., et al. Apoptosis-inducing effect of a new bisphosphonate, YM529, on various hematopoietic tumor cell lines. Biol. Pharm. Bull. 2003, 26:96-100.
26. Pandha H., Birchall L., Meyer B., Wilson N., Relph K., Anderson C., et al. Antitumor effects of aminobisphosphonates on renal cell carcinoma cell lines. J. Urol. 2006, 176:2255-2261.
27. Provisor A.J., Ettinger L.J., Nachman J.B., Krailo M.D., Makley J.T., Yunis E.J., et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J. Clin. Oncol. 1997, 15:76-84.
28. Rosen G., Murphy M.L., Huvos A.G., Gutierrez M., Marcove R.C. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer 1976, 37:1-11.
29. Schramm K., Krause K., Bittroff-Leben A., Goldin-Lang P., Thiel E., Kreuser E.D. Activated K-ras is involved in regulation of integrin expression in human colon carcinoma cells. Int. J. Cancer 2000, 87:155-164.
30. Shield K., Riley C., Quinn M.A., Rice G.E., Ackland M.L., Ahmed N. Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J. Carcinog. 2007, 6:11.
31. Stricker T.P., Dumin J.A., Dickeson S.K., Chung L., Nagase H., Parks W.C., et al. Structural analysis of the alpha2 integrin I domain/procollagenase-1 (matrix metalloproteinase-1) interaction. J. Biol. Chem. 2001, 276:29375-29381.
32. Tanimori Y., Tsubaki M., Yamazoe Y., Satou T., Itoh T., Kidera Y., et al. Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits tumor metastasis in mouse melanoma through suppression of the Rho/ROCK pathway. Clin. Exp. Metastasis 2010, 27:529-538.
33. Tsubaki M., Matsuoka H., Yamamoto C., Kato C., Ogaki M., Satou T., et al. The protein kinase C inhibitor, H7, inhibits tumor cell invasion and metastasis in mouse melanoma via suppression of ERK1/2. Clin. Exp. Metastasis 2007, 24:431-438.
34. Tsubaki M., Kato C., Nishinobo M., Ogaki M., Satou T., Ito T., et al. Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits macrophage inflammatory protein 1 alpha expression and secretion in mouse myeloma cells. Cancer Sci. 2008, 99:152-158.
35. Vincenti M.P., White L.A., Schroen D.J., Benbow U., Brinckerhoff C.E. Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): mechanisms that control enzyme activity, transcription, and mRNA stability. Crit. Rev. Eukaryot. Gene Expr. 1996, 6:391-411.
36. Yamazoe Y., Tsubaki M., Matsuoka H., Satou T., Itoh T., Kusunoki T., et al. Dimethylfumarate inhibits tumor cell invasion and metastasis by suppressing the expression and activities of matrix metalloproteinases in melanoma cells. Cell Biol. Int. 2009, 33:1087-1094.
37. Yeh M.W., Rougier J.P., Park J.W., Duh Q.Y., Wong M., Werb Z., et al. Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A. Endocr. Relat. Cancer 2006, 13:1173-1183.